SANES

9.247

-0.18%↓

BBVA

18.6

0%↓

ALV

371.9

+0.16%↑

MUV2

544.4

+0.11%↑

INGA

22.345

-0.47%↓

SANES

9.247

-0.18%↓

BBVA

18.6

0%↓

ALV

371.9

+0.16%↑

MUV2

544.4

+0.11%↑

INGA

22.345

-0.47%↓

SANES

9.247

-0.18%↓

BBVA

18.6

0%↓

ALV

371.9

+0.16%↑

MUV2

544.4

+0.11%↑

INGA

22.345

-0.47%↓

SANES

9.247

-0.18%↓

BBVA

18.6

0%↓

ALV

371.9

+0.16%↑

MUV2

544.4

+0.11%↑

INGA

22.345

-0.47%↓

SANES

9.247

-0.18%↓

BBVA

18.6

0%↓

ALV

371.9

+0.16%↑

MUV2

544.4

+0.11%↑

INGA

22.345

-0.47%↓

Search

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

205.9 1.68

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

201.8

Massimo

206.5

Metriche Chiave

By Trading Economics

Entrata

-23M

93M

Vendite

400K

745M

P/E

Media del settore

71.526

29.357

EPS

0.94

Margine di Profitto

12.43

Dipendenti

10,134

EBITDA

-55M

201M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+13.77% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-919M

19B

Apertura precedente

204.22

Chiusura precedente

205.9

Notizie sul Sentiment di mercato

By Acuity

11%

89%

16 / 528 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 nov 2025, 16:49 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 nov 2025, 15:32 UTC

Acquisizioni, Fusioni, Takeovers

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 nov 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 nov 2025, 23:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 nov 2025, 16:05 UTC

Discorsi di Mercato

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 nov 2025, 16:04 UTC

Discorsi di Mercato

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 nov 2025, 15:54 UTC

Acquisizioni, Fusioni, Takeovers

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 nov 2025, 15:44 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 nov 2025, 15:43 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 nov 2025, 15:42 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 nov 2025, 15:41 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 nov 2025, 15:11 UTC

Discorsi di Mercato

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 nov 2025, 14:26 UTC

Discorsi di Mercato

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 nov 2025, 14:11 UTC

Discorsi di Mercato

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 nov 2025, 14:11 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

27 nov 2025, 13:35 UTC

Discorsi di Mercato

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 nov 2025, 13:33 UTC

Discorsi di Mercato

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 nov 2025, 13:22 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 nov 2025, 13:22 UTC

Discorsi di Mercato

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 nov 2025, 13:17 UTC

Discorsi di Mercato

LVMH Should Be Able to Recover Next Year -- Market Talk

27 nov 2025, 11:13 UTC

Discorsi di Mercato

European Gas Prices Come Under Pressure -- Market Talk

27 nov 2025, 11:07 UTC

Utili

Genting: Positive About Prospects Over Longer Term

27 nov 2025, 11:06 UTC

Utili

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 nov 2025, 11:04 UTC

Utili

Genting: International Travel Demand Expected to Remain Resilient

27 nov 2025, 11:04 UTC

Utili

Genting: Global Growth Expected to Remain Subdued

27 nov 2025, 11:04 UTC

Utili

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 nov 2025, 10:59 UTC

Utili

Genting Bhd 3Q Net Profit Fell 86% on Year

27 nov 2025, 10:58 UTC

Utili

Genting Bhd 3Q Rev Rose 14% on Year

27 nov 2025, 10:56 UTC

Utili

Genting Bhd 3Q Net MYR30.3M

27 nov 2025, 10:56 UTC

Utili

Genting Bhd 3Q EPS MYR0.0079

Confronto tra pari

Modifica del prezzo

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

13.77% in crescita

Previsioni per 12 mesi

Media 228.57 EUR  13.77%

Alto 246 EUR

Basso 210 EUR

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

16 / 528 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat